According to the newly-launched company, the life sciences sector, which has been accelerated by the heightened global focus on health security since the onset of Covid-19, is set to be a key driver of Singapore’s future economy.
ClavystBio, a life sciences company established by CLA Real Estate Holdings, has announced its launch to accelerate the commercialisation of life sciences discoveries and innovation from Singapore.
To date, ClavystBio has committed US$220 million ($309.1 million) to six early-stage companies and three venture partners, in investments to launch Singapore-based global life sciences companies — accelerating life sciences commercialisation in Singapore.
